Archive: 16/07/2021
Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML
The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia, according to results published in Blood Cancer Discovery, ...
Jul 16, 2021